Shots:
- Gilead has entered into a strategic collaboration with LEO Pharma to develop the latter’s small molecule oral STAT6 programs targeting various inflammatory disorders
- As per the terms, Gilead secures worldwide rights to develop, manufacture & commercialize LEO’s preclinical STAT6 inhibitors & degrading proteins, with LEO having the option to co-commercialize them for dermatology outside the US. LEO also retains global rights to topical formulations of the inhibitors
- LEO Pharma is entitled for an aggregate of ~$1.7B ($250M upfront) & high single-digit to mid-teens tiered royalties on sales of oral products while Gilead will get high single-digit to mid-teens tiered royalties on sales of topical products
Ref: Gilead | Image: Terray Therapeutics & Gilead
Related News:- Gilead and Terray Therapeutics Partner to Discover and Develop Small Molecules for Various Targets
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
